Spinal Implant Sales Make, Break Orthopedic Stocks In September
This article was originally published in The Gray Sheet
Executive Summary
Biomet's ability to beat Wall Street's first-quarter revenue estimates by roughly $9 mil. due to strong spinal implant sales drove up the company's stock 12.6% in September
You may also be interested in...
OrthoLogic, dj Orthopedics Seek Alternative Paths To Healing Bones
OrthoLogic will focus on commercializing its Chrysalin synthetic peptide technology for tissue and bone repair with proceeds from the sale of its electromagnetic bone stimulation business
OrthoLogic, dj Orthopedics Seek Alternative Paths To Healing Bones
OrthoLogic will focus on commercializing its Chrysalin synthetic peptide technology for tissue and bone repair with proceeds from the sale of its electromagnetic bone stimulation business
Abiomed Pumps Up Temporary Heart Assist Offerings With AB5000 Ventricle
Abiomed expects FDA's Sept. 25 approval of a PMA supplement for its AB5000 Ventricle biventricular cardiac assist system to help reinvigorate stagnant temporary cardiac assist capital equipment sales